Key takeaway
What This Development Means
US Customs has updated entry instructions for Section 232 duties on patented pharmaceuticals and ingredients. Products of companies outside Annex III became covered on 29 September 2026, and treatment depends on product, origin, use and programme evidence.
Are All Imported Pharmaceuticals Subject To A 100% US Duty?
No. The outcome depends on whether the product is covered, patented or generic, its origin, intended use, active ingredient source and any qualifying onshoring or pricing agreement. Several headings carry 0%, 15% or 20% treatment.
Do Free-Trade Agreements Remove An Applicable Section 232 Pharmaceutical Duty?
No. Customs states that the Section 232 amount is collected in addition to an otherwise applicable preferential rate. Anti-dumping, countervailing and other duties can also continue to apply.
Source basis: US Customs And Border Protection, CSMS No. 70054007 (28 September 2026)
US Customs and Border Protection has published CSMS No. 70054007, updating entry instructions for Section 232 pharmaceutical duties under Presidential Proclamation 11020. Products of Annex III companies were covered from 31 July 2026. Goods from all other companies became subject when entered for consumption, or withdrawn from warehouse for consumption, from 12:01 am Eastern time on 29 September 2026.
The guidance reflects a 23 September Federal Register notice and corrections to the Harmonized Tariff Schedule of the United States. It covers specified classifications in Chapters 29 and 30 through headings 9903.04.60 to 9903.04.70.
Patent, Origin, Use And Agreements Determine The Entry Heading
Heading 9903.04.60 sets a 100% combined column one and Section 232 rate for covered patented pharmaceutical articles unless another heading applies. For covered products of Japan, European Union Member States, South Korea, Switzerland or Liechtenstein, heading 9903.04.62 sets the combined rate at 15%. United Kingdom-origin patented pharmaceutical articles enter under 9903.04.63 at a 0% additional rate.
Patented products under a qualifying onshoring plan use heading 9903.04.64 at 20%, increasing to 100% from 2 April 2030. A qualifying onshoring plan agreement paired with a most-favoured-nation pricing agreement can use 9903.04.65 at 0%, but that heading expires on 20 January 2029. If more than one proclamation rate applies, Customs says the lowest applicable rate controls.
Zero-rate headings remain condition-specific. Heading 9903.04.66 covers specified uses and listed jurisdictions. Heading 9903.04.67 covers generics and now expressly includes unpatented animal-health products. Heading 9903.04.68 covers dosage-form products made with a US-origin active pharmaceutical ingredient.
Heading 9903.04.69 covers listed Chapter 29 or 30 articles that are not pharmaceuticals, or are neither patented nor generic. New heading 9903.04.70 covers articles and associated ingredients used solely for clinical trials, research and development or other non-commercial purposes.
Technical Corrections Narrow And Clarify Coverage
The corrected definition of pharmaceutical articles covers finished pharmaceutical products, their active pharmaceutical ingredients and key starting materials for those ingredients. Five codes were removed from Annex IV: 2937.23.50, 3002.13.00, 3002.14.00, 3002.15.00 and 3004.49.00.
Removal from Annex IV does not by itself establish the final entry treatment. Filers must apply the corrected notes and product facts. US-origin pharmaceutical products are not subject to these proclamation duties.
Free-trade or preference eligibility does not displace an applicable Section 232 amount, while anti-dumping, countervailing and other duties may still apply. Drawback is available. Foreign-trade-zone admissions generally require privileged foreign status unless domestic status is eligible.
Classification Governance Is Now A Commercial Control
Importers should obtain evidence for patent or generic status, origin, active ingredient source, intended use and qualifying agreements before entry. Brokers need decision trees that prevent a zero-rate heading from being used on description alone.
The nominal 100% rate is not a reliable landed-cost assumption. The applicable outcome can turn on legal status and programme evidence that sit outside the tariff code, so procurement, regulatory, tax and customs records must reconcile across pharmaceutical supply chains.
Related Foresight analysis includes EU trade measures on Chinese PBTC and the EU acetylsalicylic acid investigation.
Summary
The Section 232 pharmaceutical duties are in force, and the updated guidance changes how filers apply their detailed treatment. Importers should revalidate current entries against headings 9903.04.60 to 9903.04.70 and retain evidence for patent status, origin, use, active ingredient source and programme eligibility.
Related Articles
China Opens Anti-Dumping Investigation Into EU p-Nitrotoluene Imports
China's p-nitrotoluene investigation has begun without imposing duties, and interested parties have 20 days to register.
EU Water Protection Rules Tighten Controls On PFAS And Pharmaceuticals
Directive (EU) 2026/805 strengthens EU water protection by expanding controls on PFAS, pharmaceuticals, bisphenols and emerging pollutants. The rules increase monitoring expectations, sharpen future quality standards and give ECHA a larger scientific role, creating new compliance considerations across chemicals, manufacturing, water treatment and downstream sectors.
European Commission Confirms 50-Tonne CBAM Threshold Remains Within Statutory Emissions Cap
The first published emissions assessment keeps CBAM's 50-tonne threshold unchanged and confirms that 99.13% of relevant emissions remain in scope.
